Monte Carlo planning points to 70 MeV for a shallow Hodgkin’s lymphoma target
Proton therapy gets its clinical appeal from a simple physical truth: dose rises sharply at the end of the beam range, then falls off quickly beyond the target. In Hodgkin’s lymphoma, where many patients are young and long-term toxicity matters, that property is more than a planning convenience. It is the reason investigators turned to a GATE-based Monte Carlo framework to test how beam energy and target depth interact in a simplified treatment geometry.
The study evaluated a spherical target 37 mm in diameter positioned 5–42 mm deep in a homogeneous water phantom, a setup designed to mirror commissioning-style planning conditions rather than the complexity of a full patient anatomy. Energies from 60 to 90 MeV were modeled, and the team selected the beam with the best balance between target coverage and normal tissue sparing using a weighted Target Coverage & Sparing metric. The 70 MeV beam performed best for the investigated geometry.
A single energy choice drove the entire downstream comparison.
Why the 70 MeV beam won the target coverage and sparing test
The 70 MeV plan produced a Target Coverage & Sparing value of 0.876 and covered 93.8% of the target. In practical terms, the energy was low enough to stop within the intended depth range while still delivering useful coverage across the spherical volume. Higher energies risk pushing the distal fall-off beyond the target, while lower energies can undershoot the prescribed depth and leave portions of the volume underdosed. In a disease such as Hodgkin’s lymphoma, where involved-site targets may sit near the chest and mediastinal structures, a beam that threads that narrow dosimetric window can matter as much as the nominal prescription itself.
The physics behind the result is straightforward. Proton beams deposit most of their energy near the end of their range, and the Bragg peak can be positioned by tuning beam energy to the target depth. When the beam energy is matched to anatomy, the high-dose region can be concentrated inside the lesion while minimizing dose spill into tissue beyond it. The Monte Carlo framework used here is well suited to that task because it follows particle transport with greater fidelity than simplified analytical approaches, especially in geometries where depth and distance from the target strongly influence dose gradients.
Organ doses fell steeply with distance from the target
After the target-energy selection, the analysis moved into a voxelized anthropomorphic CIRS ATOM phantom to estimate out-of-field exposure to organs at risk. Relative organ doses followed an approximately exponential decline with increasing distance from the target, ranging from 39.9 mGy in the left lung to 0.079 mGy in the thyroid per Gray of physical dose to the target. Those numbers matter because they show how quickly proton therapy can de-escalate dose outside the treated volume when geometry is favorable, while also reminding planners that nearby thoracic organs still receive measurable exposure.
The gradient is clinically intuitive. Structures close to the treatment field absorb more scattered and secondary radiation, while organs farther away are progressively shielded by distance and beam attenuation. For patients with Hodgkin’s lymphoma, especially younger patients with long survivorship horizons, even low out-of-field exposure is relevant when considering cumulative risk for late effects. The study does not calculate patient-specific second cancer risk, but it does provide a standardized dosimetric reference that can support that kind of comparison in future work.
Statistical precision stayed within tight bounds across the simulations
The simulations reported statistical uncertainties below 2% in the target volume and below 3.2% in organs at risk. Those uncertainty limits strengthen the internal consistency of the dosimetric findings and suggest the observed differences were not driven by noisy transport estimates. In a Monte Carlo study, small statistical uncertainty is especially important when the clinical question hinges on subtle differences in depth-dose behavior, because a few millimeters of range mismatch can alter target coverage and distal sparing in ways that matter for treatment planning.
The use of a standardized homogeneous water phantom for energy selection also makes the result easier to interpret. Water is not a patient, but it is the cleanest benchmark for commissioning a beam model and identifying an energy that achieves a given depth-dose profile under controlled conditions. The anthropomorphic phantom then extends that evaluation into anatomy-like geometry, where organ proximity and scatter paths are more realistic. Together, the two stages create a staged logic: first find the energy that best matches the target depth, then inspect how that choice distributes dose away from the target.
Standardized geometry, not patient-specific validation, limits immediate translation
The practical value of this work lies in its standardization. A 37 mm spherical target in a homogeneous phantom is reproducible, which makes the model useful as a reference point for comparing proton therapy plans across platforms or institutions. It also offers a stable benchmark for judging how different beam energies behave when the target sits at modest depth, a scenario that can arise in chest-adjacent Hodgkin’s lymphoma planning.
The limitation is equally clear: this is not a patient-specific analysis. Real Hodgkin’s lymphoma plans must account for individual anatomy, breathing motion, varying mediastinal geometry, and changing organ position. Those factors can alter the Bragg peak placement, the distance to lung and thyroid, and the practical balance between coverage and sparing. The authors explicitly frame the framework as a reference that requires further validation with patient-specific data before it can be treated as a planning guide for individual cases.
Even so, the dosimetric signal is direct. For a shallow mediastinal target, 70 MeV emerged as the most efficient energy in this modeled geometry, and out-of-field doses dropped rapidly as organs moved away from the target. In proton therapy, that kind of physical selectivity is the point; the next step is proving how reliably it survives the transition from phantom to patient.